Abzena PLC Result of Annual General Meeting (9951A)

TIDMABZA

RNS Number : 9951A

Abzena PLC

17 September 2018

Abzena plc

Result of Annual General Meeting

Cambridge, UK, 17 September 2018: Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, announces that at its Annual General Meeting held today at 10:00am at the offices of Pinsent Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES, all resolutions were duly passed.

Details of the votes received in relation to each of the resolutions are as follows:

 
 Resol   Vote For      % In      Votes Against   % Against   Votes      % Abstain   Total Votes 
                        favour                                Abstain 
   1     122,288,284   100       0               0           0          0           122,288,284 
        ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   2     122,288,284   100       0               0           0          0           122,288,284 
        ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   3     122,288,284   100       0               0           0          0           122,288,284 
        ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   4     122,288,284   100       0               0           0          0           122,288,284 
        ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   5     122,288,284   100       0               0           0          0           122,288,284 
        ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   6     122,288,284   100       0               0           0          0           122,288,284 
        ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   7     122,288,284   100       0               0           0          0           122,288,284 
        ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   8     122,288,284   100       0               0           0          0           122,288,284 
        ------------  --------  --------------  ----------  ---------  ----------  ------------ 
 

Percentage figures have been subject to rounding as considered appropriate.

The total number of ordinary shares of GBP0.002 each eligible to be voted at the Annual General Meeting was 214,220,399.

Enquiries:

 
   Abzena Plc 
    John Burt (Chief Executive Officer) Julian 
    Smith (Chief Financial Officer)                   [phone] 
 
   N+1 Singer (Nominated Adviser and Broker) 
    Aubrey Powell 
    Ben Farrow                                        [phone] 
   Instinctif Partners                                [phone] 
    Melanie Toyne Sewell                               [e-mail] 
    Rozi Morris 
    Alex Shaw 
 

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENA Inside products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;

   --     Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --     Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

   --     Proprietary site-specific conjugation technologies and novel payloads for ADC development; 
   --     GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and 
   --     GMP analytical services for biopharmaceutical manufacturing projects. 

For more information, please see www.abzena.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGFKODPDBKDBCD

(END) Dow Jones Newswires

September 17, 2018 07:55 ET (11:55 GMT)